Hikma Pharmaceuticals PLC

HIK.L · Moat type: REGULIERUNG

MoatScore

5/10

Fair Value

24 GBP (≈ 31.68 USD)

Margin of Safety

+33.4 %

Rating

BEOBACHTEN

Hikma Pharmaceuticals develops, manufactures and markets prescription generics, branded pharmaceuticals and injectable drugs – primarily in the USA, the MENA region and Europe – with profits derived from three segments: the high-margin injectables business, the volume-driven US generics segment and the branded business in emerging markets.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.